

Amendments to the Specification

Please replace the paragraph beginning at page 16, line 26 with the following rewritten paragraph:

Immunosuppressive agent: A molecule, such as a chemical compound, small molecule, steroid, nucleic acid molecule, or other biological agent, that can decrease an immune response such as an inflammatory reaction. Immunosuppressive agents include, but are not limited to an agent of use in treating arthritis (anti-arthritis agent). Specific, non-limiting examples of immunosuppressive agents are non-steroidal anti-inflammatory agents, cyclosporine A, FK506, and anti-CD4. In additional examples, the agent is a biological response modifier, such as ~~Kineret~~ KINERET® (anakinra), ~~Enbrel~~ ENBREL® (etanercept), or ~~Remicade~~ REMICADE® (infliximab), a disease-modifying antirheumatic drug (DMARD), such as ~~Arava~~ ARAVA® (leflunomide), a steroid, such as prednisone or cortisone, a nonsteroidal anti-inflammatory drug (NSAID), specifically a Cyclo-Oxygenase-2 (COX-2) inhibitor, such as ~~Celebrex~~ CELEBREX® (celecoxib) and ~~Vioxx~~ VIOXX® (rofecoxib), or another product, such as ~~Hyalgan~~ HYALGAN® (hyaluronan) and ~~Synvisc~~ SYNVISC® (hylan G-F20).

Please replace the paragraph beginning at page 28, line 5 with the following rewritten paragraph:

Pharmaceutical compositions that include at least one suppressive ODN as described herein as an active ingredient, or that includes both a suppressive ODN and additional agents, such as anti-inflammatory or anti-arthritis factors as active ingredients, can be formulated with an appropriate solid or liquid carrier, depending upon the particular mode of administration chosen. Additional active ingredients include, for example, biological response modifiers, such as ~~Kineret~~ KINERET® (anakinra), ~~Enbrel~~ ENBREL® (etanercept), or ~~Remicade~~ REMICADE® (infliximab), a disease-modifying antirheumatic drug (DMARD), such as ~~Arava~~ ARAVA® (leflunomide), a steroid, such as prednisone or cortisone, a nonsteroidal anti-inflammatory drug (NSAID) such as celecoxib, choline magnesium trisalicylate, diclofenac, diclofenac potassium, diclofenac XR, diflunisal, etodolac, etodolac ER, fenoprofen, flurbiprofen oral, ibuprofen,

indomethacin, indomethacin SR, indomethacin suppositories, ketoprofen, ketoprofen ER, meclofenamate, meloxicam, nabumetone, naproxen, naproxen CR, naproxen ER, oxaprozin, piroxicam, rofecoxib, salsalate, sulindac, or tolmetin sodium, or other products, such as ~~Hyalgan~~ HYALGAN® (hyaluronan) and ~~Synvise~~ SYNVISC® (hylan G-F20).

Please replace the paragraph beginning at page 30, line 23, with the following rewritten paragraph:

In particular examples, the anti-arthritis agent is a biological response modifier, such as ~~Kineret~~ KINERET® (anakinra), ~~Enbrel~~ ENBREL® (etanercept), or ~~Remicade~~ REMICADE® (infliximab), a disease-modifying antirheumatic drug (DMARD), such as ~~Arava~~ ARAVA® (leflunomide), a steroid, such as prednisone or cortisone, a nonsteroidal anti-inflammatory drug (NSAID), such as celecoxib, choline magnesium trisalicylate, diclofenac, diclofenac potassium, diclofenac XR, diflunisal, etodolac, etodolac ER, fenoprofen, flurbiprofen oral, ibuprofen, indomethacin, indomethacin SR, indomethacin suppositories, ketoprofen, ketoprofen ER, meclofenamate, meloxicam, nabumetone, naproxen, naproxen CR, naproxen ER, oxaprozin, piroxicam, rofecoxib, salsalate, sulindac, or tolmetin sodium, or another product, such as ~~Hyalgan~~ HYALGAN® (hyaluronan) or ~~Synvise~~ SYNVISC® (hylan G-F20).